Tag

Her2

All articles tagged with #her2

health1 month ago•2 min saved

FDA Grants Second National Priority Voucher-Driven Approval for Hernexeos in HER2-Mutant NSCLC

The FDA approved Hernexeos (zongertinib) for adults with unresectable or metastatic non-squamous NSCLC harboring activating HER2 (ERBB2) mutations, extending accelerated approval to first-line patients under the Commissioner's National Priority Voucher (CNPV) pilot program. The decision followed strong data showing 76% of untreated patients had substantial tumor shrinkage, higher than typical 30-45% responses, and came 44 days after filing on Jan 13, 2026. The move underscores fast-tracked review through the CNPV program, which also provides voucher-related benefits; the agency noted Breakthrough Therapy and Priority Review designations and highlighted safety risks such as hepatotoxicity and other common side effects.

via fda.gov|

#health #her2 #hernexeos

health-and-medicine2 months ago•6 min saved

CD27 boost could unlock long-lasting cancer vaccine immunity

A 20-year-old breast cancer vaccine trial shows all participants are still alive decades later, suggesting durable immune memory. Researchers found persistent CD27-marked CD4+ T cells can recognize the cancer, hinting that CD27 could make cancer vaccines more effective. In mice, combining the vaccine with a CD27-activating antibody nearly doubled tumor elimination (about 40% complete responses vs 6% with vaccine alone); adding extra support for CD8+ T cells pushed tumor rejection to ~90%. These findings imply CD27 could be a key addition to cancer vaccines and compatible with existing therapies.

via ScienceDaily|

#cancer-vaccine #cd27 #cd4-t-cells

science2 months ago•7 min saved

Decades-Old Breast Cancer Vaccine Triggers Durable Immune Memory, New Boosting Approach Emerges

Researchers studied survivors from a decades-old breast cancer vaccine trial and found they retain powerful CD27+ immune memory years later. In mice, combining a CD27-activating antibody with a HER2-targeting vaccine dramatically increased tumor rejection, largely via CD4+ T cells and, with additional CD8+ T-cell support, boosted efficacy to near 90%. The findings suggest CD4+ T cells can drive lasting anti-tumor immunity and that a single CD27 boost alongside vaccines could enhance cancer immunotherapies in humans.

via SciTechDaily|

#cancer-vaccine #cd27 #cd4-t-cells